비교리스트

 카트 문의
시장보고서
상품코드
1193138

윌슨병 치료제 시장 : 약제 종류별(페니실라민, 트리엔틴, 아연), 유통 채널별(소매 약국, 병원내 약국, 온라인 약국) - 세계 기회 분석 및 산업 예측(2021-2031년)

Wilson Disease Drugs Market By Drug Type (Penicillamine, Trientine, Zinc), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 211 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

윌슨병 치료제의 세계 시장은 2021년에 5억 9517만 달러를 차지하고, 2022년부터 2031년에 걸쳐 CAGR 3.6%를 기록했으며, 2031년에는 8억 4819만 달러에 달할 것으로 예측됩니다 .

윌슨병은 간, 뇌, 인체의 다른 중요한 장기에 구리가 축적되는 드문 유전성 질환입니다. 윌슨병 환자의 대부분은 5세에서 35세 사이에 진단되지만, 청소년과 노인에게도 발병할 수 있습니다. 구리는 건강한 신경, 뼈, 콜라겐, 피부 안료인 멜라닌의 발달에 주요한 역할을 합니다. 일반적으로 음식에서 흡수되며 잉여는 간에서 만들어진 물질 (담즙)을 통해 배설됩니다. 그러나 윌슨병 환자에서는 구리가 적절하게 배설되지 않고 대신 축적되고 때로는 생명을 위협하는 수준까지 축적됩니다. 윌슨병은 조기에 진단되면 치료가 가능하며 많은 분들이 정상적인 삶을 살고 있습니다.

윌슨병은 상염색체 열성 유전합니다. 이것은이 질병에 걸리기 위해 각 부모로부터 하나의 비정상 유전자를 상속해야한다는 것을 보여줍니다. 만약 비정상적인 유전자를 하나만 이어받은 경우, 그 사람 자신은 아프지 않을지도 모르지만, 그 사람은 보인자가 되어, 아이에게 그 유전자를 계승시킬 수 있습니다. 윌슨병은 치료되지 않은 경우 생명과 관련될 수 있습니다. 심각한 합병증으로는 간 흉터, 신장 장애, 간 부전, 지속적인 신경 장애, 정신 장애, 혈액 장애 등이 있습니다. 윌슨병 치료제 시장은 윌슨병의 유병률 증가, 약물 개발을 위한 R&D 활동의 진전, 조기 진단의 보급 등에 의해 예측 기간 동안 큰 시장 성장을 이룰 것으로 예상됩니다. 또한 연구개발에 대한 투자의 증가와 유력한 파이프라인 후보의 존재, 헬스케어 인프라의 정비를 위한 지출의 증가, 신흥국 시장에서의 질병 예방에 관한 국민의 의식의 증가, 개인화 의료에 대한 수요의 증가 등이 시장의 성장을 더욱 촉진하는 요인으로 들 수 있습니다. 그러나 윌슨병의 치료에 대한 인식이나 진단시설 부족, 합병증에 의한 높은 치료비가 시장성장의 저해요인이 될 것으로 예상됩니다. 한편, 정부의 의약품 개발에 대한 높은 투자와 건강 관리 지출의 증가는 업계에 새로운 길을 나타내는 요인이며, 윌슨병 치료제 시장에 큰 성장 기회를 가져올 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19의 시장에의 영향도 분석

제4장 윌슨병 치료제 시장 : 약물 유형별

  • 개요
    • 시장 규모 및 예측
  • 페니실라민
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 트리안틴
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 아연
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 윌슨병 치료제 시장 : 유통 채널별

  • 개요
    • 시장 규모 및 예측
  • 소매 약국
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 병원 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 온라인 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제6장 윌슨병 치료제 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 약물 유형별
    • 북미 시장 규모·예측 : 유통 채널별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모·예측 : 약물 유형별
    • 유럽 시장 규모·예측 : 유통 채널별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 약물 유형별
    • 아시아태평양의 시장 규모·예측 : 유통 채널별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 호주
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 약물 유형별
    • LAMEA의 시장 규모·예측 : 유통채널별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA 지역

제7장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 톱 기업의 포지셔닝, 2021년

제8장 기업 프로필

  • Apotex
  • ANI Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Limited
  • Lupin Ltd
  • Dr.Reddy's Laboratories Ltd
  • Bausch Health Companies Inc.
  • Panacea Biotec Ltd
  • par pharmaceutical
  • navinta llc
  • breckenridge pharmaceutical, inc.
ksm 23.03.27

The global Wilson disease drugs market accounted for $595.17 million in 2021, and is expected to reach $848.19 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.

Wilson disease is a rare inherited disorder that causes copper to accumulate in the liver, brain and other vital organs of human body. most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well. Copper plays a key role in the development of healthy nerves, bones, collagen and the skin pigment melanin. It is normally absorbed from food, and excess is excreted through a substance produced in liver (bile). However, in people with Wilson's disease, copper is not eliminated properly and instead accumulates, possibly to a life-threatening level. Wilson's disease is treatable when diagnosed early, and many people with the disorder live normal lives.

Wilson's disease is inherited as an autosomal recessive trait, this indicates that a person must inherit one copy of the defective gene from each parent in order to have the disease. If the person receives only one abnormal gene, he may not become ill himself, but he is a carrier and can pass the gene to children. Untreated Wilson's disease can be fatal. Serious complications include scaring of liver, kidney problems, liver failure, persistent neurological problems, psychological problems, and blood problems. Wilson disease drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine which further facilitate the growth of the market. However, lack of awareness and diagnosis facility associated with Wilson disease treatment and high treatment cost due to complications are expected to impede the market growth. In contrast, high investment by the government for drug development and increase in healthcare expenditure are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the Wilson disease drugs market.

The Wilson disease drugs market is segmented on the basis of drug type, distribution channel and region. Depending on drug type, the market is classified into Penicillamine, Trientine and Zinc. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global Wilson disease drugs market. The key companies profiled in the report include ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Breckenridge Pharmaceutical, Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, NAVINTA LLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vivet Therapeutics

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wilson disease drugs market analysis from 2021 to 2031 to identify the prevailing wilson disease drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the wilson disease drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global wilson disease drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Trientine
  • Zinc
  • Penicillamine

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Apotex
    • ANI Pharmaceuticals Inc
    • Teva Pharmaceutical Industries Limited
    • Lupin Ltd
    • Dr.Reddy's Laboratories Ltd
    • Bausch Health Companies Inc.
    • Panacea Biotec Ltd
    • par pharmaceutical
    • navinta llc
    • breckenridge pharmaceutical, inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
    • 3.4.2.Restraints
    • 3.4.3.Opportunities
  • 3.5.COVID-19 Impact Analysis on the market

CHAPTER 4: WILSON DISEASE DRUGS MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Penicillamine
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Trientine
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Zinc
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Retail Pharmacies
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Hospital Pharmacies
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Online Pharmacies
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country

CHAPTER 6: WILSON DISEASE DRUGS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Drug Type
    • 6.2.3 North America Market size and forecast, by Distribution Channel
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Key market trends, growth factors and opportunities
      • 6.2.4.1.2 Market size and forecast, by Drug Type
      • 6.2.4.1.3 Market size and forecast, by Distribution Channel
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Key market trends, growth factors and opportunities
      • 6.2.4.2.2 Market size and forecast, by Drug Type
      • 6.2.4.2.3 Market size and forecast, by Distribution Channel
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Key market trends, growth factors and opportunities
      • 6.2.4.3.2 Market size and forecast, by Drug Type
      • 6.2.4.3.3 Market size and forecast, by Distribution Channel
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Drug Type
    • 6.3.3 Europe Market size and forecast, by Distribution Channel
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Key market trends, growth factors and opportunities
      • 6.3.4.1.2 Market size and forecast, by Drug Type
      • 6.3.4.1.3 Market size and forecast, by Distribution Channel
      • 6.3.4.2 France
      • 6.3.4.2.1 Key market trends, growth factors and opportunities
      • 6.3.4.2.2 Market size and forecast, by Drug Type
      • 6.3.4.2.3 Market size and forecast, by Distribution Channel
      • 6.3.4.3 UK
      • 6.3.4.3.1 Key market trends, growth factors and opportunities
      • 6.3.4.3.2 Market size and forecast, by Drug Type
      • 6.3.4.3.3 Market size and forecast, by Distribution Channel
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Key market trends, growth factors and opportunities
      • 6.3.4.4.2 Market size and forecast, by Drug Type
      • 6.3.4.4.3 Market size and forecast, by Distribution Channel
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Key market trends, growth factors and opportunities
      • 6.3.4.5.2 Market size and forecast, by Drug Type
      • 6.3.4.5.3 Market size and forecast, by Distribution Channel
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Key market trends, growth factors and opportunities
      • 6.3.4.6.2 Market size and forecast, by Drug Type
      • 6.3.4.6.3 Market size and forecast, by Distribution Channel
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Drug Type
    • 6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Key market trends, growth factors and opportunities
      • 6.4.4.1.2 Market size and forecast, by Drug Type
      • 6.4.4.1.3 Market size and forecast, by Distribution Channel
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Key market trends, growth factors and opportunities
      • 6.4.4.2.2 Market size and forecast, by Drug Type
      • 6.4.4.2.3 Market size and forecast, by Distribution Channel
      • 6.4.4.3 India
      • 6.4.4.3.1 Key market trends, growth factors and opportunities
      • 6.4.4.3.2 Market size and forecast, by Drug Type
      • 6.4.4.3.3 Market size and forecast, by Distribution Channel
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Key market trends, growth factors and opportunities
      • 6.4.4.4.2 Market size and forecast, by Drug Type
      • 6.4.4.4.3 Market size and forecast, by Distribution Channel
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Key market trends, growth factors and opportunities
      • 6.4.4.5.2 Market size and forecast, by Drug Type
      • 6.4.4.5.3 Market size and forecast, by Distribution Channel
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Key market trends, growth factors and opportunities
      • 6.4.4.6.2 Market size and forecast, by Drug Type
      • 6.4.4.6.3 Market size and forecast, by Distribution Channel
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Drug Type
    • 6.5.3 LAMEA Market size and forecast, by Distribution Channel
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Key market trends, growth factors and opportunities
      • 6.5.4.1.2 Market size and forecast, by Drug Type
      • 6.5.4.1.3 Market size and forecast, by Distribution Channel
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Key market trends, growth factors and opportunities
      • 6.5.4.2.2 Market size and forecast, by Drug Type
      • 6.5.4.2.3 Market size and forecast, by Distribution Channel
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Key market trends, growth factors and opportunities
      • 6.5.4.3.2 Market size and forecast, by Drug Type
      • 6.5.4.3.3 Market size and forecast, by Distribution Channel
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Key market trends, growth factors and opportunities
      • 6.5.4.4.2 Market size and forecast, by Drug Type
      • 6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.5. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

  • 8.1 Apotex
    • 8.1.1 Company overview
    • 8.1.2 Key Executives
    • 8.1.3 Company snapshot
    • 8.1.4 Operating business segments
    • 8.1.5 Product portfolio
    • 8.1.6 Business performance
    • 8.1.7 Key strategic moves and developments
  • 8.2 ANI Pharmaceuticals Inc
    • 8.2.1 Company overview
    • 8.2.2 Key Executives
    • 8.2.3 Company snapshot
    • 8.2.4 Operating business segments
    • 8.2.5 Product portfolio
    • 8.2.6 Business performance
    • 8.2.7 Key strategic moves and developments
  • 8.3 Teva Pharmaceutical Industries Limited
    • 8.3.1 Company overview
    • 8.3.2 Key Executives
    • 8.3.3 Company snapshot
    • 8.3.4 Operating business segments
    • 8.3.5 Product portfolio
    • 8.3.6 Business performance
    • 8.3.7 Key strategic moves and developments
  • 8.4 Lupin Ltd
    • 8.4.1 Company overview
    • 8.4.2 Key Executives
    • 8.4.3 Company snapshot
    • 8.4.4 Operating business segments
    • 8.4.5 Product portfolio
    • 8.4.6 Business performance
    • 8.4.7 Key strategic moves and developments
  • 8.5 Dr.Reddy's Laboratories Ltd
    • 8.5.1 Company overview
    • 8.5.2 Key Executives
    • 8.5.3 Company snapshot
    • 8.5.4 Operating business segments
    • 8.5.5 Product portfolio
    • 8.5.6 Business performance
    • 8.5.7 Key strategic moves and developments
  • 8.6 Bausch Health Companies Inc.
    • 8.6.1 Company overview
    • 8.6.2 Key Executives
    • 8.6.3 Company snapshot
    • 8.6.4 Operating business segments
    • 8.6.5 Product portfolio
    • 8.6.6 Business performance
    • 8.6.7 Key strategic moves and developments
  • 8.7 Panacea Biotec Ltd
    • 8.7.1 Company overview
    • 8.7.2 Key Executives
    • 8.7.3 Company snapshot
    • 8.7.4 Operating business segments
    • 8.7.5 Product portfolio
    • 8.7.6 Business performance
    • 8.7.7 Key strategic moves and developments
  • 8.8 par pharmaceutical
    • 8.8.1 Company overview
    • 8.8.2 Key Executives
    • 8.8.3 Company snapshot
    • 8.8.4 Operating business segments
    • 8.8.5 Product portfolio
    • 8.8.6 Business performance
    • 8.8.7 Key strategic moves and developments
  • 8.9 navinta llc
    • 8.9.1 Company overview
    • 8.9.2 Key Executives
    • 8.9.3 Company snapshot
    • 8.9.4 Operating business segments
    • 8.9.5 Product portfolio
    • 8.9.6 Business performance
    • 8.9.7 Key strategic moves and developments
  • 8.10 breckenridge pharmaceutical, inc.
    • 8.10.1 Company overview
    • 8.10.2 Key Executives
    • 8.10.3 Company snapshot
    • 8.10.4 Operating business segments
    • 8.10.5 Product portfolio
    • 8.10.6 Business performance
    • 8.10.7 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제